Jessica Allen

@KUMedicine alum | IM via @CUInternalMed | Current PGY4 @UtahHemeOnc @HuntsmanCancer Fellow | interested in lymphoma and QOL

[Jessica Allen @JessicaAllenMD]

Oral agents have changed the CLL treatment landscape. But how does their cost affect patients? Here's a review of our #ASH24 abstract on the relationship between financial toxicity, medication adherence, and health-related QOL in CLL pts on 1L oral therapy #lymsm 🧵/1

[TheLiverDoc™ @theliverdoc]

This is the silent part that people wouldn't know.

Behind closed doors inside a medical conference, a large group of clinicians and researchers giving a standing ovation to another group of clinicians and researchers who found a way to increase survival in patients suffering from one of the, if not the, worst cancer in humans.

Metastatic pancreatic cancer.

They'll do this and then be on their way to see their patients the next day as if nothing happened.

And then work on something new to better what they did in this room.

That is how medical science works.
Value it and value its practitioners.

[NEJM @NEJM]

Original Article: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (phase 3 RASolute 302 trial) https://t.co/y4G27hfORg

#ASCO26 | @ASCO

[Samuel Hume @DrSamuelBHume]

One of the most amazing things I’ve ever seen: a standing ovation for the full Daraxonrasib results

I feel inspired and energised, to put it mildly — we have a targeted therapy for pancreatic cancer now, and nothing is undruggable anymore

[Anirban Maitra @Aiims1742]

The overall survival curves for Daraxonrasib in 2nd line advanced #PancreaticCancer leave no doubt how impactful this advance is for the field & for patients. Congratulations Brian Wolpin, @EileenMOReilly & @md_oberstein et al.
A seminal #ASCO26 plenary!
https://t.co/ub099PSsOq

[Anirban Maitra @Aiims1742]

Don’t typically see these kinds of headlines in #PancreaticCancer but today’s #ASCO26 plenary on @RevMedicines Daraxonrasib brings it.
‘Landmark’ pancreatic cancer drug keeps patients alive for twice as long
By @Carolynyjohnson @washingtonpost
https://t.co/d8SGmfKJHW

[Jessica Allen @JessicaAllenMD]

This is truly so exciting. My dad was diagnosed with pancreatic cancer the week before my college graduation, and he was the reason I went into oncology. I am so excited to see this progress for patients like him.

[Mark Lewis, MD, FASCO @marklewismd]

As many other oncologists will also attest, we were taught this was a dead end

It was, dogmatically, never going to work — kras was too much of a “greasy ball” to be targeted

And yet here we are, with truly meaningful survival curves👇

Inspiration on multiple levels #ASCO26

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Jessica Allen @JessicaAllenMD]

@mana1981 @majorajay My 19 year old self, who very consciously chose to take public speaking as an online course, would not believe her eyes!

[Jessica Allen @JessicaAllenMD]

Honored to present our CUBIC study on real-world outcomes in bispecific antibodies in relapsed/refractory follicular lymphoma. In a cohort of 99 patients, these therapies appear similarly as safe and effective as demonstrated in clinical trial populations. Manuscript coming soon!

[Jessica Allen @JessicaAllenMD]

Biggest thanks to my mentors Dr. Alli Bock and Dr. Sairah Ahmed, my co-author Rahul Shah, and all participating CUBIC institutions. It was also very special to present on a panel led by one of my mentors at Colorado, @mana1981, and to collaborate with another CU mentor @majorajay

[Ajay Major, MD, MBA @majorajay]

And, ePRO monitoring has an OS benefit! #ASCO26
- ~40k pts across 6 health systems using EHR-integrated eSyM system
eSyM users had better OS than non-users:
- Chemo: HR 0.63, absolute 1-yr OS benefit 10.2%
- Surg onc: HR 0.58, absolute 1-yr OS benefit 2.8%
Many of our anti-cancer therapies don't even have this level of evidence! #onctwitter

[Ajay Major, MD, MBA @majorajay]

RW bispecific outcomes R/R FL (CUBIC Consortium) #ASCO26
- 99 pts, median 3 prior lines, 15% prior CAR
- ORR 87%, CRR 72%
- 1-yr PFS 72%, 18-mo OS 92%
- PFS not affected by BsAb type or prior CAR
- outcomes similar for older/very elderly pts
- CRS 34% (mostly G1, no G3+), ICANS 3% (all G1)
Encouraging data for BsAb across diverse/heavily pretreated FL, including older adults. #lymsm #geriheme
https://t.co/Mb67UxWYeK

[CU Anschutz Lymphoma Program @CULymphoma]

Congratulations to former @CUMedicalSchool resident Dr. @JessicaAllenMD on her #ASCO26 oral presentation on real-world outcomes of bispecifics in R/R FL, from the CUBIC Consortium. Multiple @CUHematology faculty contributed. #lymsm
https://t.co/NoRnMzYlxT

[Jessica Allen @JessicaAllenMD]

Congratulations to an incredible physician and person!

[UofUHeme @UofUHematology]

to Dr. Gli Fortuna for being accepted into the prestigious ASH CRTI! @ash_hematology @UofUInternalMed @UofUHealth

[Ajay Major, MD, MBA @majorajay]

Our study on patient-reported time toxicity of BsAb in R/R FL & DLBCL:
- 120 pts actively receiving BsAb tx
- fixed-duration BsAb (glofi, mosun) = less healthcare contact days & ~50% less time burden (vs epco)
- no difference in infusion time between IV and SQ
Time-limited & less frequent BsAb dosing translates into meaningful reductions in time toxicity, both in the clinic and at home. #lymsm
https://t.co/ci6lfcT5Ol

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

It’s strange that we ask trainees to read clinical trials but never really teach them how to read clinical trials.
I’d request all training program directors and mentors to please share this article to their trainees and fellows- https://t.co/HJhZlsAS4u

Grateful to @JCOOP_ASCO for making this free.

[Dr Amol Akhade @SuyogCancer]

What are plenary sessions for ASCO 2026 ?
Titles are just out
Watch out 🙂👇 @ASCO #asco2026 @Alfdoc2 @APassaroMD @dr_yakupergun @OncBrothers @OncoAlert @MedwatchKate @FordePatrick @DrJNaidoo @MyriamChalabi @DrChoueiri

[Conquer Cancer, the ASCO Foundation @ConquerCancerFd]

Conquer Cancer is thrilled to announce our support of 141 recipients of 2026 ASCO Annual Meeting Merit Awards and 5 Special Merit Awards. These awards support students and trainees with outstanding research for presentation at the 2026 ASCO Meeting. Special Merit Awards are presented to top-ranking abstracts. See the list of recipients: https://t.co/69JlOGClEp

@ASCO #ASCO26 #ResearchConquersCancer #ConquerCancer

[Eddie Cliff @Eddie_Cliff]

🚨Just out @CCR_AACR 🚨

V proud of our manuscript on polatuzumab efficacy by cell of origin in DLBCL

We show COO by Hans predicts pola sensitivity in 740 pts

Pts w R/R non-GCB DLBCL have higher ORR, CRR & PFS

Massive thanks @dgermain21 & collabs!

https://t.co/kGyRneMAuo

[CU Anschutz Lymphoma Program @CULymphoma]

Dr. @majorajay @CUHematology contributed (with @JessicaAllenMD) to a large multicenter study of real-world outcomes of polatuzumab in frontline and relapsed/refractory DLBCL, now published @CCR_AACR. #lymsm
https://t.co/mXeNONq0U9